Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control.

Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control. Abstract Text:

Henry T Lynch,Ramon M Fusaro,Jane F Lynch,

Oncologists who are aware of the progress in hereditary cancer syndrome diagnosis, and, in particular, of how this effort may be effectively facilitated through a comprehensive family history in concert with molecular genetic studies, are in the envious position of designing highly targeted screening and management programs for the membership of these cancer-prone families. The Lynch syndrome is discussed as a clinical model wherein the presence of mismatch repair mutations provides a high level of diagnostic certainty for the initiation of targeted cancer screening and management. The familial atypical multiple mole melanoma-pancreatic cancer (FAMMM-PC) syndrome, on the other hand, provides another model with cancer-control potential. Given its phenotypic features of multiple atypical nevi, high total body mole count and cutaneous malignant melanoma, coupled with the integral association of PC in a subset of FAMMM kindreds with the CDKN2A germline mutation, this may result in a perhaps lower level of diagnostic certainty when compared with the Lynch syndrome. This knowledge may impact upon progress in the earlier diagnosis of melanoma and provide an impetus for creative diagnostic methods in PC, a disease that, at this time, demonstrates a mortality rate virtually identical to its incidence rate.

Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control. Publishing Authors By Initials

HT Lynch,RM Fusaro,JF Lynch,

For similar neoplasms: neoplasms by site: digestive system neoplasms: pancreatic neoplasms research abstracts see: neoplasms: neoplasms by site: digestive system neoplasms: pancreatic neoplasms research

PUBMED ID PMID:

MEDLINE DATE:

Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control. Journal Published:

PUBLICATION TYPE: Review

Journal: Future oncology (London, England)

VOLUME: 3

Page Numbers: 169-81

Journal Abbreviation:

ISSN: 1479-6694

DAY: 3

MONTH: Apr

YEAR: 2007

Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control. Information

Number of References: 69

LANGUAGE: eng

NlmUniqueID: 101256629

Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control. Keywords Mesh Terms:

KEYWORDS: Pancreatic Neoplasms

MESH TERMS: genetics

Chemical & Substance for Abstract: Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control. Information

Substance Name: Cyclin-Dependent Kinase Inhibitor p16

Registry Number: 0

Grant and Affiliation Information for Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control.

AFFILIATION: Department of Preventive Medicine, Creighton University School of Medicine, Omaha NE 68178, USA. htlynch@creighton.edu

Country: England

AGENCY: United States NCI

GRANT: 1U01 CA 86389

ACRONYM: CA

MEDLINETA: Future Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control Related Publications

• Amphibian lipid levels at metamorphosis correlate to post-metamorphic terrestrial survival.
• Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus.
• Changes in synaptic morphology accompany actin signaling during LTP.
• Chronic hypersensitivity pneumonitis: CT features comparison with pathologic evidence of fibrosis and survival.
• Clinical selection of candidates for mutational testing for cancer susceptibility.
• Current and emerging strategies for the management of sarcoidosis.
• Dietary fish oil deactivates a growth-promoting signaling pathway in hepatoma 7288CTC in Buffalo rats.
• Diindolylquinoxalines: effective indole-based receptors for phosphate anion.
• ENG mutations in MADH4/BMPR1A mutation negative patients with juvenile polyposis.
• Evidence that long-term potentiation occurs within individual hippocampal synapses during learning.
• Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease.
• Follicular development during early pregnancy and the estrous cycle of the sow.
• Fyn-mediated phosphorylation of NR2B Tyr-1336 controls calpain-mediated NR2B cleavage in neurons and heterologous systems.
• GAD antibody positive paraneoplastic stiff person syndrome in a patient with renal cell carcinoma.
• Global analysis of alternative splicing during T-cell activation.
• Grade III Gliomas with Imaging Appearances of Glioblastoma should be Managed as Glioblastoma.
• Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control.
• Large global effective population sizes in Paramecium.
• Nutrient signaling components controlling protein synthesis in striated muscle.
• Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma.
• Pharmacological therapy for Wegener's granulomatosis.
• Presence or absence of lipopolysaccharide O antigens affects type III secretion by Pseudomonas aeruginosa.
• Rapamycin blunts nutrient stimulation of eIF4G, but not PKCepsilon phosphorylation, in skeletal muscle.
• Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
• Results from an autonomous underwater vehicle towed hydrophone array experiment in Nantucket Sound.
• Tantalus, a 240MeV Dedicated Source of Synchrotron Radiation, 1968-1986.
• The effect of maternal socio-economic status throughout the lifespan on infant birthweight.
• The relative roles of three DNA repair pathways in preventing Caenorhabditis elegans mutation accumulation.
• Toward a consensus in molecular diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome).
• Who should be sent for genetic testing in hereditary colorectal cancer syndromes?